Pazopanib in pretreated advanced neuroendocrine tumors: A phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

Annals of Oncology

Volumn 26, Issue 9, 2015, Pages 1987-1993

  Grande, Enrique ^a   Capdevila, J ^b   Castellano, D ^c   Teule A ^d   Duran I ^e   Fuster, J ^f   Sevilla, I ^g   Escudero, P ^h   Sastre, J ⁱ   Garcia Donas J ^j   Casanovas, O ^d   Earl, J ^a   Ortega, L ⁱ   Apellaniz Ruiz, M ^k   Rodriguez Antona, C ^k   Alonso Gordoa, T ^a   Diez J J ^a   Carrato, A ^a   Garcia Carbonero R ^e  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^e UNIVERSITY OF SEVILLE   (Spain)

^f HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^h HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j Centro Integral Oncologico Clara Campal   (Spain)

^k CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

more..

Author keywords

Angiogenic markers; Bronchial carcinoids; Gastroenteropancreatic tumors; Pazopanib; Polymorphisms; Thymic tumors

Indexed keywords

ALKALINE PHOSPHATASE; GAMMA GLUTAMYLTRANSFERASE; HYPOXIA INDUCIBLE FACTOR 1; LACTATE DEHYDROGENASE; PAZOPANIB; SOMATOSTATIN DERIVATIVE; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TUMOR MARKER; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ADULT; AGED; ANEMIA; ANOREXIA; APPETITE DISORDER; ARTICLE; ASTHENIA; BRAIN HEMATOMA; CANCER SURVIVAL; CELL COUNT; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL TUMOR; HAIR DEPIGMENTATION; HAIR DISEASE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; HYPOREFLEXIA; HYPOREXIA; INSOMNIA; LIVER TOXICITY; LUNG TUMOR; MALE; MISSENSE MUTATION; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; OBSTRUCTIVE JAUNDICE; OVERALL SURVIVAL; PAIN; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RISK BENEFIT ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMNOLENCE; SURVIVAL TIME; THYMOMA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VEGFR3 GENE; VOMITING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84941661216     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv252     Document Type: Article

References (14)

1. Castellano D, Capdevila J, Sastre J et al. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). Eur J Cancer 2013; 49(18): 3780-3787.
2. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
3. Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513.
4. Pavel ME, Hainsworth JD, Baudin E et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378(9808): 2005-2012.
5. Castellano D, Grande E, Barriuso J. Advances in pancreatic neuroendocrine tumor treatment. N Engl J Med 2011; 364(19): 1872-1873.
6. Salazar R, Wiedenmann B, Rindi G et al. ENETS 2011 Consensus Guidelines for the Management of Patients with digestive Neuroendocrine Tumors: an update. Neuroendocrinology 2012; 95: 71-73.
7. Kumar R, Crouthamel MC, Rominger DH et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009; 101: 1717-1723.
8. Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist 2010; 15: 539-547.
9. Ahn HK, Choi JY, Kim KM et al. Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours. Br J Cancer 2013; 109(6): 1414-1419.
10. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
11. Phan A, Yao JC, Fogelman DR et al. A prospective, multi-institutional phase II study of GW786034 ( pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 2010; 28 (15 suppl): abstr 4001.
12. Raymond E, García-Carbonero R, Wiedenmann B et al. Systemic therapeutic strategies for GEP-NETS: what can we expect in the future? Cancer Metastasis Rev 2014; 33(1): 367-372.
13. Khan MS, Kirkwood A, Tsigani T et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol 2013; 31(3): 365-372.
14. García-Donas J, Esteban E, Leandro-García LJ et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicenter, observational, prospective study. Lancet Oncol 2011; 12: 1143-1150.